| pubmed-article:17581918 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17581918 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:17581918 | lifeskim:mentions | umls-concept:C0079774 | lld:lifeskim |
| pubmed-article:17581918 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:17581918 | lifeskim:mentions | umls-concept:C0383429 | lld:lifeskim |
| pubmed-article:17581918 | lifeskim:mentions | umls-concept:C1413947 | lld:lifeskim |
| pubmed-article:17581918 | lifeskim:mentions | umls-concept:C0055598 | lld:lifeskim |
| pubmed-article:17581918 | lifeskim:mentions | umls-concept:C1708063 | lld:lifeskim |
| pubmed-article:17581918 | lifeskim:mentions | umls-concept:C1096776 | lld:lifeskim |
| pubmed-article:17581918 | lifeskim:mentions | umls-concept:C0023981 | lld:lifeskim |
| pubmed-article:17581918 | lifeskim:mentions | umls-concept:C0206012 | lld:lifeskim |
| pubmed-article:17581918 | lifeskim:mentions | umls-concept:C1178562 | lld:lifeskim |
| pubmed-article:17581918 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:17581918 | pubmed:dateCreated | 2007-9-20 | lld:pubmed |
| pubmed-article:17581918 | pubmed:abstractText | To evaluate in a prospective multicenter trial the feasibility and clinical efficacy of the combination of alemtuzumab (Campath-1H) with the cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) regimen (CHOP-C) as the primary treatment for patients with peripheral T-cell lymphoma (PTCL), between January 2003 and December 2005, 24 consecutive patients with PTCL entered the study and received 8 CHOP courses. Alemtuzumab was added at 30 mg subcutaneously at day -1 initially to the first 4 courses (4 patients), and then to all 8 courses (20 patients). Complete remission (CR) was achieved in 17 (71%) patients, 1 had partial remission, and 6 had stable/progressive disease. At a median follow-up of 16 months (range, 5-42 months), 14 patients were alive, 9 had died from progressive disease, and 1 had died from pneumonia at day +198 while in CR. So far, 13 are disease-free, with an overall median duration of response of 11 months. The most frequent side effects were grade 4 neutropenia and cytomegalovirus (CMV) reactivation. Major infections were Jacob-Creutzfeldt (J-C) virus reactivation, pulmonary invasive aspergillosis, Staphylococcus sepsis, and pneumonia. This study shows that CHOP-C: (1) is a feasible chemoimmunotherapy regimen; (2) is effective in PTCL with a high rate of CR achievement; and (3) is associated with mostly manageable infectious complications. This clinical trial was registered with the Osservatorio Nazionale sulla Sperimentazione cinica as ID no. 141202. | lld:pubmed |
| pubmed-article:17581918 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17581918 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17581918 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:17581918 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17581918 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17581918 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17581918 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17581918 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17581918 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17581918 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17581918 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17581918 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17581918 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17581918 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17581918 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17581918 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17581918 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:17581918 | pubmed:issn | 0006-4971 | lld:pubmed |
| pubmed-article:17581918 | pubmed:author | pubmed-author:TarellaCorrad... | lld:pubmed |
| pubmed-article:17581918 | pubmed:author | pubmed-author:BillioAttoA | lld:pubmed |
| pubmed-article:17581918 | pubmed:author | pubmed-author:ZajaFrancesco... | lld:pubmed |
| pubmed-article:17581918 | pubmed:author | pubmed-author:IannittoEmili... | lld:pubmed |
| pubmed-article:17581918 | pubmed:author | pubmed-author:PileriStefano... | lld:pubmed |
| pubmed-article:17581918 | pubmed:author | pubmed-author:LevisAlessand... | lld:pubmed |
| pubmed-article:17581918 | pubmed:author | pubmed-author:RigacciLuigiL | lld:pubmed |
| pubmed-article:17581918 | pubmed:author | pubmed-author:GallaminiAndr... | lld:pubmed |
| pubmed-article:17581918 | pubmed:author | pubmed-author:PattiCaterina... | lld:pubmed |
| pubmed-article:17581918 | pubmed:author | pubmed-author:TucciAlessand... | lld:pubmed |
| pubmed-article:17581918 | pubmed:author | pubmed-author:TorchioPierfe... | lld:pubmed |
| pubmed-article:17581918 | pubmed:author | pubmed-author:MannaAnnunzia... | lld:pubmed |
| pubmed-article:17581918 | pubmed:author | pubmed-author:ZoliValerioV | lld:pubmed |
| pubmed-article:17581918 | pubmed:author | pubmed-author:SpecchiaMaria... | lld:pubmed |
| pubmed-article:17581918 | pubmed:author | pubmed-author:SecondoVicenz... | lld:pubmed |
| pubmed-article:17581918 | pubmed:author | pubmed-author:PintoAntonell... | lld:pubmed |
| pubmed-article:17581918 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17581918 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:17581918 | pubmed:volume | 110 | lld:pubmed |
| pubmed-article:17581918 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17581918 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17581918 | pubmed:pagination | 2316-23 | lld:pubmed |
| pubmed-article:17581918 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:17581918 | pubmed:meshHeading | pubmed-meshheading:17581918... | lld:pubmed |
| pubmed-article:17581918 | pubmed:meshHeading | pubmed-meshheading:17581918... | lld:pubmed |
| pubmed-article:17581918 | pubmed:meshHeading | pubmed-meshheading:17581918... | lld:pubmed |
| pubmed-article:17581918 | pubmed:meshHeading | pubmed-meshheading:17581918... | lld:pubmed |
| pubmed-article:17581918 | pubmed:meshHeading | pubmed-meshheading:17581918... | lld:pubmed |
| pubmed-article:17581918 | pubmed:meshHeading | pubmed-meshheading:17581918... | lld:pubmed |
| pubmed-article:17581918 | pubmed:meshHeading | pubmed-meshheading:17581918... | lld:pubmed |
| pubmed-article:17581918 | pubmed:meshHeading | pubmed-meshheading:17581918... | lld:pubmed |
| pubmed-article:17581918 | pubmed:meshHeading | pubmed-meshheading:17581918... | lld:pubmed |
| pubmed-article:17581918 | pubmed:meshHeading | pubmed-meshheading:17581918... | lld:pubmed |
| pubmed-article:17581918 | pubmed:meshHeading | pubmed-meshheading:17581918... | lld:pubmed |
| pubmed-article:17581918 | pubmed:meshHeading | pubmed-meshheading:17581918... | lld:pubmed |
| pubmed-article:17581918 | pubmed:meshHeading | pubmed-meshheading:17581918... | lld:pubmed |
| pubmed-article:17581918 | pubmed:meshHeading | pubmed-meshheading:17581918... | lld:pubmed |
| pubmed-article:17581918 | pubmed:meshHeading | pubmed-meshheading:17581918... | lld:pubmed |
| pubmed-article:17581918 | pubmed:meshHeading | pubmed-meshheading:17581918... | lld:pubmed |
| pubmed-article:17581918 | pubmed:meshHeading | pubmed-meshheading:17581918... | lld:pubmed |
| pubmed-article:17581918 | pubmed:meshHeading | pubmed-meshheading:17581918... | lld:pubmed |
| pubmed-article:17581918 | pubmed:meshHeading | pubmed-meshheading:17581918... | lld:pubmed |
| pubmed-article:17581918 | pubmed:meshHeading | pubmed-meshheading:17581918... | lld:pubmed |
| pubmed-article:17581918 | pubmed:meshHeading | pubmed-meshheading:17581918... | lld:pubmed |
| pubmed-article:17581918 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17581918 | pubmed:articleTitle | Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. | lld:pubmed |
| pubmed-article:17581918 | pubmed:affiliation | Hematology Department, Ospedale Santa Croce, Cuneo, Italy. gallamini.a@ospedale.cuneo.it | lld:pubmed |
| pubmed-article:17581918 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17581918 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:17581918 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17581918 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17581918 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17581918 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17581918 | lld:pubmed |
